Aidea Pharma(SH:688488) Xin Lang Cai Jing·2025-09-19 06:12Group 1 - The core point of the news is that Aidi Pharmaceutical's stock price dropped by 5.03% to 14.74 CNY per share, with a total market capitalization of 6.202 billion CNY as of the report date [1] - Aidi Pharmaceutical, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province, and focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The company's revenue composition includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment, reagents, and others at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - Among Aidi Pharmaceutical's top ten circulating shareholders, one fund from GF Fund Management, the GF Value Core Mixed A (010377), entered the top ten in the second quarter, holding 3.931 million shares, which is 0.93% of the circulating shares [2] - The GF Value Core Mixed A fund, established on January 22, 2021, has a latest scale of 3.516 billion CNY, with a year-to-date return of 62.56% and a one-year return of 110.84% [2] - The fund manager, Wu Yuanyi, has been in position for nearly 4 years, with the fund's total asset scale at 20.478 billion CNY and a best return of 112.4% during his tenure [3]